Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases

Articles

A Turning Point: INGREZZA’s Impact on Huntingto...

Huntington’s disease is an incurable, rare genetic, progressive neurodegenerative disorder. According to the National Organization for Rare Disorders (NORD), about 30,000 people in the United State...

Sep 18, 2023

myelodysplastic-syndrome-treatment
Myelodysplastic Syndrome Treatment Market: Unveiling the Robust Pipeline

The number of people diagnosed with myelodysplastic syndrome in the US each year is unknown. However, some estimates have put this number at about 10,000, while other estimates have been much higher. Moreover, myelodysplastic syndrome is uncommon before age 50, and the risk increases as a person gets older. It is a...

Find More
Biosurgery Market Analysis
Biosurgery: Advancing Medicine through Biologically Derived Solutions

In recent years, the healthcare and medical devices market has undergone a remarkable transformation, largely fueled by advancements in technology and growth in innovation. One of the major standout developments in the healthcare industry is the rise of the biosurgery market and the related product demand, whic...

Find More
bms-and-janssen-multiple-myeloma-treatment-drugs-landscape
BMS Vs. Janssen: Which Company Will Dominate The Multiple Myeloma Treatment Market This Decade?

Over the past several years, multiple myeloma treatment options have expanded widely for patients, resulting in significantly improved outcomes. The FDA approved around 16 new agents and 30 treatment regimens, transforming the multiple myeloma treatment paradigm for patients with newly diagnosed and relapsed/refrac...

Find More

More Views & Analysis

antibody-drug-conjugates-adcs-in-lung-cancer-treatment
A Quick Review of Antibody-Drug Conjugates (ADCs) in Lung Cancer: HER2, TROP-2, HER3, MET, and CEACAM5 ADC Advancements

Lung cancer remains the leading cause of cancer-related death in the United States. The American Cancer Society estimates 238,340 people will be diagnosed with lung cancer in 2023, with non-small cell lung cancer (NSCLC) accounting for the majority of cases (roughly 80% to 85%).The treatment paradigm of antibody-dr...

Find More

Pain Management Devices Market
Revolutionizing Pain Management: The Growth in Innovative Devices and Rise of Market

Chronic pain is an unwelcome companion in the journey of life and can significantly impact the quality of life. Being in pain serves as a protective mechanism that warns us when something is wrong with the concerned body part, and is a natural component of the human experience. But for millions of people around the...

Find More

fabry-disease-treatment
Fabry Disease – A Market Perspective On The Emerging Pipeline

Fabry disease is a rare hereditary lysosomal storage disorder that is caused by mutation in the GLA gene located on the X chromosome. The defect leads to the deficiency of an enzyme called alpha-galactosidase A, responsible for the breakdown of globotriaosylceramide (Gb3). The accumulation of the fatty substance le...

Find More

cd38-directed-therapies-for-multiple-myeloma-treatment
Unleashing the Potential: CD38 Directed Therapies Revolutionize Multiple Myeloma Treatment

The landscape of multiple myeloma treatment has undergone a profound transformation with the advent of monoclonal antibodies (mAbs) targeting CD38. Among the notable breakthroughs, two anti-CD38 mAbs, DARZALEX (daratumumab) and SARCLISA (isatuximab-irfc), have been approved for clinical use. These groundbreaking mu...

Find More

Light Therapy Market Assessment
Harnessing Light for Health: Evaluating the Growing Demand for Light Therapy

In recent years, the rapid development of technology and innovation has sped up the transformation of the healthcare and well-being industry. Among the various emerging and evolving trends, Light Therapy is one of the key technologies gaining immense attention among the users. Light Therapy is an ancient practice, ...

Find More

bispecific-antibodies-for-multiple-myeloma-treatment
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

Step aside, CAR-Ts; with three FDA approvals, the class of bispecific antibodies has begun to take on the relapsed/refractory multiple myeloma treatment segment. Currently, the US Food and Drug Administration (FDA) has authorized 10 bispecific antibodies and one bispecific molecule, the majority of which are a...

Find More

COVID-19 transforms healthcare facets at an unprecedented pace. Based on emerging technology, we can.....

Find More

Nonalcoholic steatohepatitis (NASH) affects individuals slowly and progressively. Presently, there e.....

Find More

The pharma industry has played a crucial role in fighting against the pandemic situation by supplyin.....

Find More

Postoperative Pain is the pain that an individual experiences after a major operation or surgical pr.....

Find More

With its innovative approach, chimeric antigen receptor T cell therapy created a new dawn in the age.....

Find More

End-Stage Renal Disease (ESRD) occurs when chronic kidney disease (CKD) has reached the stage where .....

Find More